Immune phenotype in children with therapy-naïve remitted and relapsed Crohn's disease

World Journal of Gastroenterology

Volumn 16, Issue 47, 2010, Pages 6001-6009

  Cseh, Aron ^a   Vasarhelyi, Barna ^a,b   Molnar, Kriszta ^a   Szalay, Balazs ^a   Svec, Peter ^a   Treszl, Andras ^a   Dezsofi, Antal ^b   Lakatos, Peter Laszlo ^b   Arato, Andras ^b   Tulassay, Tivadar ^b   Veres, Gabor ^b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Crohn's disease; Dendritic cell; Infliximab; Lymphocyte; Monocyte; Regulatory T cell; Relapse; Remission; Therapy na ve; Toll like receptor

Indexed keywords

INFLIXIMAB; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; INNATE IMMUNITY; LYMPHOCYTE; MALE; MONOCYTE; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; REGULATORY T LYMPHOCYTE; RELAPSE; REMISSION; TH1 CELL; TH2 CELL;

EID: 78650628298     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i47.6001     Document Type: Article

References (55)

1. Dubinsky M. Special issues in pediatric inflammatory bowel disease. World J Gastroenterol 2008; 14: 413-420
2. Nieuwenhuis EE, Escher JC. Early onset IBD: what's the difference? Dig Liver Dis 2008; 40: 12-15
3. Shaoul R, Karban A, Reif S, Weiss B, Shamir R, Tamir A, Davidovich O, Halevi J, Silver EL, Levine A. Disease behavior in children with Crohn's disease: the effect of disease duration, ethnicity, genotype, and phenotype. Dig Dis Sci 2009; 54: 142-150
4. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009; 15: 199-207
5. Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology 2008; 125: 145-153
6. van Lierop PP, Samsom JN, Escher JC, Nieuwenhuis EE. Role of the innate immune system in the pathogenesis of inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009; 48: 142-151
7. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407
8. Chamouard P, Monneaux F, Richert Z, Voegeli AC, Lavaux T, Gaub MP, Baumann R, Oudet P, Muller S. Diminution of Circulating CD4+CD25 high T cells in naïve Crohn's disease. Dig Dis Sci 2009; 54: 2084-2093
9. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005; 128: 1868-1878
10. Saruta M, Yu QT, Fleshner PR, Mantel PY, Schmidt-Weber CB, Banham AH, Papadakis KA. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol 2007; 125: 281-290
11. Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, Nakamura T, Koganei K, Fukushima T, Watanabe M. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004; 173: 3119-3130
12. Roman LI, Manzano L, De La Hera A, Abreu L, Rossi I, Alvarez-Mon M. Expanded CD4+CD45RO+ phenotype and defective proliferative response in T lymphocytes from patients with Crohn's disease. Gastroenterology 1996; 110: 1008-1019
13. Alkim C, Balci M, Alkim H, Daǧli U, Parlak E, Tezel A, Ulker A. The importance of peripheral immune cells in inflammatory bowel disease. Turk J Gastroenterol 2007; 18: 82-88
14. García de Tena J, Manzano L, Leal JC, San Antonio E, Sualdea V, Alvarez-Mon M. Active Crohn's disease patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells. J Clin Immunol 2004; 24: 185-196
15. Rose M, Hildebrandt M, Fliege H, Seibold S, Mönnikes H, Klapp BF. T-cell immune parameters and depression in patients with Crohn's disease. J Clin Gastroenterol 2002; 34: 40-48
16. Liu ZX, Hiwatashi N, Noguchi M, Toyota T. Increased expression of costimulatory molecules on peripheral blood monocytes in patients with Crohn's disease. Scand J Gastroenterol 1997; 32: 1241-1246
17. Senju M, Hulstaert F, Lowder J, Jewell DP. Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and Crohn's disease. Gut 1991; 32: 779-783
18. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009; 15: 199-207
19. Baumgart DC, Metzke D, Schmitz J, Scheffold A, Sturm A, Wiedenmann B, Dignass AU. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut 2005; 54: 228-236
20. Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, Lehnardt S, Dörffel Y, Sturm A, Scheffold A, Schmitz J, Radbruch A. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin Exp Immunol 2009; 157: 423-436
21. Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, Kamm MA, Stagg AJ. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005; 129: 50-65
22. Frolova L, Drastich P, Rossmann P, Klimesova K, Tlaskalova-Hogenova H. Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J Histochem Cytochem 2008; 56: 267-274
23. Kamada N, Hisamatsu T, Honda H, Kobayashi T, Chinen H, Kitazume MT, Takayama T, Okamoto S, Koganei K, Sugita A, Kanai T, Hibi T. Human CD14+ macrophages in intestinal lamina propria exhibit potent antigen-presenting ability. J Immunol 2009; 183: 1724-1731
24. Cantó E, Ricart E, Monfort D, González-Juan D, Balanzó J, Rodríguez-Sánchez JL, Vidal S. TNF alpha production to TLR2 ligands in active IBD patients. Clin Immunol 2006; 119: 156-165
25. Grimm MC, Pavli P, Van de Pol E, Doe WF. Evidence for a CD14+ population of monocytes in inflammatory bowel disease mucosa--implications for pathogenesis. Clin Exp Immunol 1995; 100: 291-297
26. van Ierssel GJ, van der Sluys Veer A, Verspaget HW, Griffioen G, van Hogezand RA, Lamers CB. Contribution of plasma cortisol to corticosteroid-suppressed peripheral blood natural killer cell activity in Crohn's disease. Immunopharmacology 1995; 29: 11-17
27. Grose RH, Thompson FM, Baxter AG, Pellicci DG, Cummins AG. Deficiency of invariant NK T cells in Crohn's disease and ulcerative colitis. Dig Dis Sci 2007; 52: 1415-1422
28. Kontiainen S, Scheinin T, Halme L. Number of activated T-helper cells and NK cells in peripheral blood is decreased in severe Crohn's disease. APMIS 1996; 104: 355-361
29. Mack DR, Beedle S, Warren J, Davis J, Gross T. Peripheral blood intracellular cytokine analysis in children newly diagnosed with inflammatory bowel disease. Pediatr Res 2002; 51: 328-332
30. Holland N, Dong J, Garnett E, Shaikh N, Huen K, Harmatz P, Olive A, Winter HS, Gold BD, Cohen SA, Baldassano RN, Kirschner BS, Heyman MB. Reduced intracellular T-helper 1 interferon-gamma in blood of newly diagnosed children with Crohn's disease and age-related changes in Th1/Th2 cytokine profiles. Pediatr Res 2008; 63: 257-262
31. Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, Ectors N, Cortot A, Capron M, Colombel JF. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997; 113: 118-126
32. Jo Y, Matsumoto T, Yada S, Fujisawa K, Esaki M, Onai N, Matsushima K, Iida M. CCR4 is an up-regulated chemokine receptor of peripheral blood memory CD4+ T cells in Crohn's disease. Clin Exp Immunol 2003; 132: 332-338
33. Perminow G, Reikvam DH, Lyckander LG, Brandtzaeg P, Vatn MH, Carlsen HS. Increased number and activation of colonic macrophages in pediatric patients with untreated Crohn's disease. Inflamm Bowel Dis 2009; 15: 1368-1378
34. Szebeni B, Veres G, Dezsõfi A, Rusai K, Vannay A, Mraz M, Majorova E, Arató A. Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol 2008; 151: 34-41
35. Diefenbach KA, Breuer CK. Pediatric inflammatory bowel disease. World J Gastroenterol 2006; 12: 3204-3212
36. Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs 2007; 67: 1703-1723
37. Ricciardelli I, Lindley KJ, Londei M, Quaratino S. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Immunology 2008; 125: 178-183
38. Ferkolj I, Ihan A, Markovic S, Veceric Z, Pohar M. Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease. J Gastrointestin Liver Dis 2006; 15: 231-235
39. Aeberli D, Seitz M, Jüni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford) 2005; 44: 172-175
40. Maurice MM, van der Graaff WL, Leow A, Breedveld FC, van Lier RA, Verweij CL. Treatment with monoclonal antitumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 2166-2173
41. Richez C, Schaeverbeke T, Dumoulin C, Dehais J, Moreau JF, Blanco P. Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab. Arthritis Res Ther 2009; 11: R100
42. Balanescu A, Radu E, Nat R, Regalia T, Bojinca V, Ionescu R, Balanescu S, Savu C, Predeteanu D. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients. Int J Clin Pharmacol Res 2005; 25: 9-18
43. Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase- dependent pathway. Gastroenterology 2001; 121: 1145-1157
44. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22-28
45. De Rycke L, Vandooren B, Kruithof E, De Keyser F, Veys EM, Baeten D. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005; 52: 2146-2158
46. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1-7
47. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, Griffiths AM, Katz AJ, Grand RJ, Boyle JT. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12: 439-447
48. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753
49. Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am 2003; 32: 967-995, viii
50. Diefenbach KA, Breuer CK. Pediatric inflammatory bowel disease. World J Gastroenterol 2006; 12: 3204-3212
51. Svec P, Vásárhelyi B, Pászthy B, Körner A, Kovács L, Tulassay T, Treszl A. Do regulatory T cells contribute to Th1 skewness in obesity? Exp Clin Endocrinol Diabetes 2007; 115: 439-443
52. Selby WS, Jewell DP. T lymphocyte subsets in inflammatory bowel disease: peripheral blood. Gut 1983; 24: 99-105
53. Yuan SZ, Hanauer SB, Kluskens LF, Kraft SC. Circulating lymphocyte subpopulations in Crohn's disease. Gastroenterology 1983; 85: 1313-1318
54. Kool M, Lambrecht BN. Dendritic cells in asthma and COPD: opportunities for drug development. Curr Opin Immunol 2007; 19: 701-710
55. de Heer HJ, Hammad H, Kool M, Lambrecht BN. Dendritic cell subsets and immune regulation in the lung. Semin Immunol 2005; 17: 295-303